ATE525401T1 - Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene - Google Patents

Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene

Info

Publication number
ATE525401T1
ATE525401T1 AT08015250T AT08015250T ATE525401T1 AT E525401 T1 ATE525401 T1 AT E525401T1 AT 08015250 T AT08015250 T AT 08015250T AT 08015250 T AT08015250 T AT 08015250T AT E525401 T1 ATE525401 T1 AT E525401T1
Authority
AT
Austria
Prior art keywords
mhc class
tumor antigen
peptide antigens
antigens derived
relates
Prior art date
Application number
AT08015250T
Other languages
English (en)
Inventor
Richard Harrop
William Shingler
Susan Kingsman
Original Assignee
Oxford Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0509835A external-priority patent/GB0509835D0/en
Priority claimed from GB0516303A external-priority patent/GB0516303D0/en
Application filed by Oxford Biomedica Ltd filed Critical Oxford Biomedica Ltd
Application granted granted Critical
Publication of ATE525401T1 publication Critical patent/ATE525401T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT08015250T 2005-05-13 2006-05-12 Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene ATE525401T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0509835A GB0509835D0 (en) 2005-05-13 2005-05-13 Peptide
GB0516303A GB0516303D0 (en) 2005-08-08 2005-08-08 Peptide

Publications (1)

Publication Number Publication Date
ATE525401T1 true ATE525401T1 (de) 2011-10-15

Family

ID=37396923

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08015250T ATE525401T1 (de) 2005-05-13 2006-05-12 Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene

Country Status (7)

Country Link
US (1) US8147838B2 (de)
EP (3) EP2045268B1 (de)
JP (1) JP4926168B2 (de)
AT (1) ATE525401T1 (de)
AU (1) AU2006245512B2 (de)
CA (1) CA2606287A1 (de)
WO (1) WO2006120473A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059252A2 (en) * 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP2758438A1 (de) * 2011-09-23 2014-07-30 Amgen Research (Munich) GmbH Bispezifische bindende moleküle für 5t4 und cd3
AU2012335618A1 (en) * 2011-11-11 2014-06-12 Woomera Therapeutics Antagonists for abnormal vasopressin V2 receptor and uses thereof
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570940B2 (en) 1982-11-30 1988-03-31 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for producing poxvirus recombinants for expression offoreign genes
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
CA1340203C (en) 1987-09-16 1998-12-15 Noboru Yanagida Recombinant apivoxvirus
WO1989007947A1 (en) 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
WO1991000047A1 (en) 1989-06-30 1991-01-10 The Regents Of The University Of California Retrovirus detection
US5118672A (en) 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
JPH0813274B2 (ja) 1990-08-13 1996-02-14 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド
AU3635695A (en) 1994-09-19 1996-04-09 Board Of Trustees Of The Leland Stanford Junior University Methods for genetically modifying hematopoietic stem cells
EP0859856A2 (de) 1995-11-08 1998-08-26 Whitehead Institute For Biomedical Research Stabile verpackungszellinie, die pseudotyp-retroviren produziert
US6133027A (en) 1996-08-07 2000-10-17 City Of Hope Inducible expression system
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
GB9720465D0 (en) 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
GB2345063B (en) 1997-09-23 2002-07-24 Oxford Biomedica Ltd Method
US5965381A (en) 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
AU758949B2 (en) 1998-05-19 2003-04-03 Avidex Limited Multivalent T cell receptor complexes
ATE435297T1 (de) 1998-05-22 2009-07-15 Oxford Biomedica Ltd Retrovirales verabreichungssystem
CA2351622A1 (en) 1998-11-18 2000-05-25 Oxford Biomedica (Uk) Limited Polypeptide
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
GB0203419D0 (en) * 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
GB0203420D0 (en) 2002-02-13 2002-04-03 Oxford Biomedica Ltd Peptide
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
GB0520067D0 (en) * 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer

Also Published As

Publication number Publication date
AU2006245512A1 (en) 2006-11-16
EP2045268A1 (de) 2009-04-08
JP4926168B2 (ja) 2012-05-09
EP2277918A2 (de) 2011-01-26
EP2277918A3 (de) 2011-05-11
EP2277918B1 (de) 2012-11-14
JP2008539752A (ja) 2008-11-20
CA2606287A1 (en) 2006-11-16
AU2006245512B2 (en) 2011-12-22
US20090280138A1 (en) 2009-11-12
US8147838B2 (en) 2012-04-03
WO2006120473A2 (en) 2006-11-16
EP1888634A2 (de) 2008-02-20
WO2006120473A3 (en) 2008-03-06
EP2045268B1 (de) 2011-09-21

Similar Documents

Publication Publication Date Title
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
UA103202C2 (ru) Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний
CY1114050T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
ATE451388T1 (de) Tumorassoziierte peptide, die promiskuitiv an humane leukozytenantigen- (hla-) moleküle der klasse ii binden
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
CY1118369T1 (el) Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
UA109633C2 (uk) Антитіло людини проти тканинного фактора
ATE494303T1 (de) An humane leukozytenantigen-(hla-)klasse-i- oder ii-moleküle bindende tumorassoziierte peptide und damit im zusammenhang stehender impfstoff gegen krebs
EP1844077A4 (de) Dr5-antikörper und deren verwendung
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
CY1117922T1 (el) Her2/neu-eiδika αντισωματα και μεθοδοι χρησης αυτων
UA105760C2 (uk) Антитіло проти bst2
CY2022028I1 (el) Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
MX2008008185A (es) Antigenos de acido des-n-acetil-sialico, anticuerpos para los mismos, y metodos de uso en la terapia de cancer.
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene
ATE451393T1 (de) Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln
DK1730196T3 (da) EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst
AU2018256601A1 (en) Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer
CY1116887T1 (el) Anti-cd19 αντισωματα και χρησεις στην ογκολογια

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties